日韩av大片在线观看欧美成人不卡|午夜先锋看片|中国女人18毛片水多|免费xx高潮喷水|国产大片美女av|丰满老熟妇好大bbbbbbbbbbb|人妻上司四区|japanese人妻少妇乱中文|少妇做爰喷水高潮受不了|美女人妻被颜射的视频,亚洲国产精品久久艾草一,俄罗斯6一一11萝裸体自慰,午夜三级理论在线观看无码

青旗(上海)生物技術(shù)發(fā)展有限公司
中級會員 | 第5年

4006560232

當前位置:青旗(上海)生物技術(shù)發(fā)展有限公司>>細胞庫>>細胞系>> 人非小細胞肺癌細胞NCI-H358

人非小細胞肺癌細胞NCI-H358

參  考  價面議
具體成交價以合同協(xié)議為準

產(chǎn)品型號

品       牌其他品牌

廠商性質(zhì)生產(chǎn)商

所  在  地上海市

更新時間:2023-06-29 12:58:30瀏覽次數(shù):603次

聯(lián)系我時,請告知來自 化工儀器網(wǎng)
同類優(yōu)質(zhì)產(chǎn)品更多>
供貨周期 現(xiàn)貨 規(guī)格 T25培養(yǎng)瓶x1 1.5ml凍存管x2
貨號 BFN60800666 應(yīng)用領(lǐng)域 醫(yī)療衛(wèi)生,生物產(chǎn)業(yè)
主要用途 僅供科研
青旗(上海)生物技術(shù)發(fā)展有限公司,總部位于上海浦東新區(qū),依托本地高校資源,,逐步發(fā)展成為以生物技術(shù)為主的研發(fā)、生產(chǎn),、培訓為一體的綜合化產(chǎn)業(yè)平臺,,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產(chǎn)經(jīng)營原代細胞、細胞系,、ELISA試劑盒,、感受態(tài)細胞和HPLC檢測等科研產(chǎn)品與服務(wù)。我們秉承對用戶負責的態(tài)度,,以對科研的高度嚴謹,,以嚴格的質(zhì)量控制,為廣大生物醫(yī)學科研用戶提供更優(yōu)質(zhì)的服務(wù),!

細胞名稱

人非小細胞肺癌細NCI-H358                  

img1

貨物編碼

BFN60800666

產(chǎn)品規(guī)格

T25培養(yǎng)x1

1.5ml凍存x2

細胞數(shù)量

1x10^6

1x10^6

保存溫度

37

-198

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研用途                  1類

 

培養(yǎng)體系

DMEM高糖培養(yǎng)基Hyclone+10%胎牛血清Gibco+1%雙抗Hyclone

培養(yǎng)溫度

37

二氧化碳濃度

5%

簡介

人非小細胞肺癌細NCI-H358細胞于1981年從一位開始化療之前的患者的腫瘤組織中分離建株,。超微結(jié)構(gòu)研究表明細胞質(zhì)中Clara細胞的特征結(jié)構(gòu)細胞表達主要的肺表面結(jié)合蛋SP-A的蛋白RNA。不表SP-BSP-C,。他們在軟瓊脂中的克隆形成效率0.83%,。 

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Doubling time: 38 hours (in RPMI 1640 + 10% FBS), 76 hours (in ACL-3), 60 hours (in ACL-3 + BSA) (PubMed=3940644); 38 hours (ECACC).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep phosphoproteome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Caution: We are not certain that NCI-H358 and NCI-H358M are identical.

Misspelling: H1358; In PubMed=1311061 table 1.

STR信息

 Amelogenin:X,YCSF1PO:11,,12,;D13S317:812,;D16S539:12,,13D18S51:14,;D19S433:13,,14D21S11:28,,30,;D2S1338:1723,;D3S1358:14,,18D5S818:10,12,;D7S820:10,,11D8S1179:13,,14,;FGA:20,21TH01:6,;TPOX:8,,9vWA:17

參考文獻

PubMed=3940644

Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

Cancer Res. 46:798-806(1986)

 

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

 

PubMed=2388294; DOI=10.1093/jnci/82.17.1420

McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M., McMahon N.A., Eggleston J.C., Boyd M.R.

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

J. Natl. Cancer Inst. 82:1420-1426(1990)

 

PubMed=2386953

Gazdar A.F., Linnoila R.I., Kurita Y., Oie H.K., Mulshine J.L., Clark J.C., Whitsett J.A.

Peripheral airway cell differentiation in human lung cancer cell lines.

Cancer Res. 50:5481-5487(1990)

 

PubMed=1311061

Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Oncogene 7:171-180(1992)

 

PubMed=1565469

Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P., Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F., Linnoila R.I.

Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

Oncogene 7:743-749(1992)

 

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

 

PubMed=8806101; DOI=10.1002/jcb.240630514

Lokshin A., Levitt M.L.

Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.

J. Cell. Biochem. 63 Suppl. 24:186-197(1996)

 

PubMed=9649128; DOI=10.1038/bjc.1998.361

Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.

Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

Br. J. Cancer 77:2162-2170(1998)

 

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

 

PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0

Luk C., Tsao M.-S., Bayani J., Shepherd F., Squire J.A.

Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

Cancer Genet. Cytogenet. 125:87-99(2001)

 

PubMed=12068308; DOI=10.1038/nature00766

Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

 

PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Cell 131:1190-1203(2007)

 

PubMed=19472407; DOI=10.1002/humu.21028

Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

A gene-alteration profile of human lung cancer cell lines.

Hum. Mutat. 30:1199-1206(2009)

 

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112

Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.H., Diao L., Masrorpour F., Shen L., Liu W., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Cancer Discov. 2:798-811(2012)

 

PubMed=24135919; DOI=10.1038/ncomms3617

Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X., Nesvizhskii A.I., Chinnaiyan A.M.

Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

Nat. Commun. 4:2617-2617(2013)

 

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

 

PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

Differential effector engagement by oncogenic KRAS.

Cell Rep. 22:1889-1902(2018)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

 

驗收細胞注意事 

1,、收到人非小細胞肺癌細NCI-H358細胞,,請查看瓶子是否有破裂,,培養(yǎng)基是否漏出,是否渾濁,,如有請盡快聯(lián)系 

2,、收到人非小細胞肺癌細NCI-H358細胞,,如包裝完好,請在顯微鏡下觀察細胞,。,由于運輸過程中的問題,,細胞培養(yǎng)瓶中的貼壁細胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現(xiàn)細胞懸浮的情況,,出現(xiàn)此狀態(tài)時,,請不要打開細胞培養(yǎng)瓶,應(yīng)立即將培養(yǎng)瓶置于細胞培養(yǎng)箱里靜 3-5 小時左右,,讓細胞先穩(wěn)定下,,再于顯微鏡下觀察,此時多數(shù)細胞會重新貼附于瓶壁,。如細胞仍不能貼壁,,請用臺盼藍染色法鑒定細胞活力,如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理,。 

3,、收到人非小細胞肺癌細NCI-H358細胞后,請鏡下觀察細胞,,用恰當方式處理細胞,。若懸浮的細胞較多,請離心收集細胞,,接種到一個新的培養(yǎng)瓶中,。棄掉原液,使用新鮮配制的培養(yǎng)基,,使用進口胎牛血清,。剛接到細胞,若細胞不多 血清濃度可以加 15%去培養(yǎng),。若細胞迏 80% ,,血清濃度還是 10 

4,、收到人非小細胞肺癌細NCI-H358細胞時如無異常情 ,,請在顯微鏡下觀察細胞密度,如為貼壁細胞,,未超80%匯合度時,,將培養(yǎng)瓶中培養(yǎng)基吸出,,留 5-10ML 培養(yǎng)基繼續(xù)培養(yǎng):超 80%匯合度時,請按細胞培養(yǎng)條件傳代培養(yǎng),。如為懸浮細胞,,吸出培養(yǎng)液1000 轉(zhuǎn)/分鐘離 3 分鐘,,吸出上清,,管底細胞用新鮮培養(yǎng)基懸浮細胞后移回培養(yǎng)瓶 

5,、將培養(yǎng)瓶置 37培養(yǎng)箱中培養(yǎng),,蓋子微微擰松。吸出的培養(yǎng)基可以保存在滅菌過的瓶子里,,存放 4冰箱,,以備不時之需 

6,、24 小時后,,人非小細胞肺癌細NCI-H358細胞形態(tài)已恢復(fù)并貼滿瓶壁,即可傳代,。(貼壁細胞)將培養(yǎng)瓶里的培養(yǎng)基倒去,, 3-5ml(以能覆蓋細胞生長面為準PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,,消化時間以具體細胞為準,,一 1-3 分鐘,不超 5 分鐘,??梢苑?/span>37培養(yǎng)箱消化。輕輕晃動瓶壁,,見細胞脫落下來,,加 3-5ml 培養(yǎng)基終止消化。用移液管輕輕吹打瓶壁上的細胞,,使之*脫落,,然后將溶液吸入離心管內(nèi)離心1000rpm/5min,。棄上清,,視細胞數(shù)量決定分瓶數(shù),一般一傳二,,如細胞量多可一傳三,,有些細胞不易傳得過稀,有些生長較快的細胞則可以多傳幾瓶,,以具體細胞和經(jīng)驗為準,。(懸浮細胞)用移液管輕輕吹打瓶壁,,直接將溶液吸入離心管離心即可 

7,、貼壁細 ,,懸浮細胞。嚴格無菌操作,。換液時,,換新的細胞培養(yǎng)瓶和換新鮮的培養(yǎng)液37,,5%CO2 培養(yǎng)。

 

特別提醒 原瓶中培養(yǎng)基不宜繼續(xù)使用,,請更換新鮮培養(yǎng)基培養(yǎng),。

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏,!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復(fù)您~
撥打電話
在線留言